TBF1.F - Canntab Therapeutics Limited
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Show:
Annual
Income Statement
All numbers in thousandsBreakdown
ttm
2019-05-31
2018-05-31
2017-12-31
2017-05-31
2016-12-31
2015-12-31
Total Revenue
363
240
27
0
0
942
-
Cost of Revenue
-
-
-
-
-
-
-
Gross Profit
-
-
-
-
-
-
-
Operating Expenses
Research Development
123
128
141
-
41
-
-
Selling General and Administrative
2,497
2,437
2,258
188
1,074
312
174
Total Operating Expenses
2,840
2,742
2,450
188
1,117
312
174
Operating Income or Loss
-2,477
-2,502
-2,423
-188
-1,117
631
-174
Interest Expense
-
-
-
-
-
-
-
Total Other Income/Expenses Net
-
-
-
6
-
-111
0
Income Before Tax
-2,452
-2,459
-2,408
-182
-1,116
520
-174
Income Tax Expense
-
-
-
-
-
-
-
Income from Continuing Operations
-2,452
-2,459
-2,408
-182
-1,116
520
-174
Net Income
-2,452
-2,459
-2,408
-182
-1,116
520
-174
Net Income available to common shareholders
-2,452
-2,459
-2,408
-182
-1,116
520
-174
Reported EPS
Basic
-
-0.10
-0.11
-0.40
-0.07
1.20
-0.80
Diluted
-
-0.10
-0.11
-0.40
-0.07
1.00
-0.80
Weighted average shares outstanding
Basic
-
25,299
21,129
556
15,000
452
230
Diluted
-
25,299
21,129
556
15,000
520
230
EBITDA
-
-2,421
-2,372
-188
-1,115
631
-174